COMPASS Pathways plc (FRA:5Y6)
Germany · Delayed Price · Currency is EUR 4.600
+0.120 (2.68%)
At close: Dec 1, 2025
COMPASS Pathways Company Description
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.
It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS Pathways plc
| Country | United Kingdom |
| Founded | 2020 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 166 |
| CEO | Kabir Nath |
Contact Details
Address: 33 Broadwick Street London, W1F 0DQ United Kingdom | |
| Website | compasspathways.com |
Stock Details
| Ticker Symbol | 5Y6 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kabir Nath | Chief Executive Officer |
| Teri Loxam | Chief Financial Officer |
| Stephen Schultz | Head of Investor Relations |